Presentation

Xspray Pharma is a pharmaceutical company focused on developing improved and generic versions of marketed drugs. The company’s initial focus is on the orally administered drugs of the protein kinase inhibitor (PKI) class within precision oncology. Xspray’s products are based on the patented RightSize technology. The leading product candidates, Dasynoc™ (HyNap-Dasa), HyNap-Sora and HyNap-Nilo, are stable amorphous and improved versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Nexavar® (sorafenib) and Tasigna® (nilotinib), respectively.

Recent highlights
In January this year, US FDA has accepted Dasynoc’s NDA which triggers a review period of ten months until expected decision.

Outlook
In June, Bristol Myers Squibb Company (BMS) filed a sue case against Xspray for potential patent infringement and to prevent Dasynoc from entering the market. In such case, the approval could be delayed up to 30 months. Based on our patent due diligence, we however believe, that Xspray will be able to clear Dasynoc in court earlier or that BMS could enter a licensing deal with Xspray.